Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)

  • Technology appraisal
  • TA879
  • Published: 

Tools and resources

Guidance into practice